Literature DB >> 19240076

Comparative in vitro activity of REP3123 against Clostridium difficile and other anaerobic intestinal bacteria.

Diane M Citron1, Yumi A Warren, Kerin L Tyrrell, Vreni Merriam, Ellie J C Goldstein.   

Abstract

OBJECTIVES: The aim of this study was to determine the anaerobic spectrum of activity of REP3123, a novel diaryldiamine that inhibits bacterial methionyl-tRNA synthetases in Gram-positive bacteria.
METHODS: Fifty recent clinical isolates of Clostridium difficile from patients diagnosed with C. difficile infection and 223 other intestinal normal flora anaerobes were tested for their susceptibility to REP3123 and four or five comparator agents by the agar dilution method using supplemented Brucella agar with 5% laked sheep blood.
RESULTS: All strains of C. difficile were inhibited by 0.5-1 mg/L REP3123, including those resistant to moxifloxacin and clindamycin. REP3123 lacked activity against many normal flora anaerobes in the gut, including Clostridium ramosum, bifidobacteria, lactobacilli of the Lactobacillus casei-rhamnosus-plantarum group and Gram-negative anaerobes.
CONCLUSIONS: REP3123 demonstrated good potency against C. difficile, but limited activity against many other intestinal anaerobic species, thus, in theory, maintaining the colonization resistance barrier.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19240076     DOI: 10.1093/jac/dkp037

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

Review 1.  Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections.

Authors:  Michael G Dieterle; Krishna Rao; Vincent B Young
Journal:  Ann N Y Acad Sci       Date:  2018-09-21       Impact factor: 5.691

Review 2.  Intestinal colonization resistance.

Authors:  Trevor D Lawley; Alan W Walker
Journal:  Immunology       Date:  2013-01       Impact factor: 7.397

Review 3.  Clinical update for the diagnosis and treatment of Clostridium difficile infection.

Authors:  Edward C Oldfield; Edward C Oldfield; David A Johnson
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-02-06

Review 4.  Anaerobic infections: update on treatment considerations.

Authors:  Elisabeth Nagy
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

5.  Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.

Authors:  Diane M Citron; Kerin L Tyrrell; C Vreni Merriam; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

6.  Safety, Tolerability, Systemic Exposure, and Metabolism of CRS3123, a Methionyl-tRNA Synthetase Inhibitor Developed for Treatment of Clostridium difficile, in a Phase 1 Study.

Authors:  Seema U Nayak; J McLeod Griffiss; Jeffrey Blumer; Mary Ann O'Riordan; Wesley Gray; Robin McKenzie; Robert A Jurao; Amanda T An; Melissa Le; Stacie J Bell; Urs A Ochsner; Thale C Jarvis; Nebojsa Janjic; Jonathan M Zenilman
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

7.  Structure of Leishmania major methionyl-tRNA synthetase in complex with intermediate products methionyladenylate and pyrophosphate.

Authors:  Eric T Larson; Jessica E Kim; Frank H Zucker; Angela Kelley; Natascha Mueller; Alberto J Napuli; Christophe L M J Verlinde; Erkang Fan; Frederick S Buckner; Wesley C Van Voorhis; Ethan A Merritt; Wim G J Hol
Journal:  Biochimie       Date:  2010-12-07       Impact factor: 4.079

Review 8.  A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.

Authors:  Csaba Fehér; Alex Soriano; Josep Mensa
Journal:  Infect Dis Ther       Date:  2016-12-01

Review 9.  Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.

Authors:  Lissa S Tsutsumi; Yaw B Owusu; Julian G Hurdle; Dianqing Sun
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

Review 10.  Novel Antimicrobials for the Treatment of Clostridium difficile Infection.

Authors:  Nicola Petrosillo; Guido Granata; Maria Adriana Cataldo
Journal:  Front Med (Lausanne)       Date:  2018-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.